NDAORALCAPSULEPriority Review
Approved
May 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PYTEST (Urea, C-14) is an oral capsule diagnostic agent approved in 1997 for detecting Helicobacter pylori infection via breath testing. This radiopharmaceutical uses a labeled urea compound that is metabolized by H. pylori urease, enabling non-invasive diagnosis of gastric infection.
LOE Approaching
Product is in late-stage lifecycle with modest competitive pressure (30%), signaling a consolidating or declining commercial organization focused on operational efficiency.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
PYTEST currently shows zero linked job openings, reflecting its mature LOE-approaching status with limited growth opportunities. Career advancement on this product would focus on operational excellence and commercial optimization rather than expansion or innovation.
Product ManagerField Sales Representative
Worked on PYTEST at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.